Merouane Bencherif

Summary

Affiliation: Targacept Inc
Country: USA

Publications

  1. ncbi request reprint Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia
    Aaron J Kucinski
    Department of Pathology and Anatomical Sciences, University of Buffalo, NY, USA
    Curr Pharm Biotechnol 12:437-48. 2011
  2. doi request reprint Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia
    Merouane Bencherif
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101 4165, USA
    Med Hypotheses 78:594-600. 2012
  3. doi request reprint Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance
    Merouane Bencherif
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    Acta Pharmacol Sin 30:702-14. 2009
  4. ncbi request reprint Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors
    Merouane Bencherif
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    J Mol Neurosci 30:17-8. 2006
  5. doi request reprint Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology?
    Merouane Bencherif
    Preclinical Research, Targacept, Inc, Suite 300, Winston Salem, NC 27101 4165, USA
    Med Hypotheses 74:281-5. 2010
  6. pmc Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases
    Merouane Bencherif
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
    Cell Mol Life Sci 68:931-49. 2011
  7. ncbi request reprint Targeting neuronal nicotinic receptors: a path to new therapies
    Merouane Bencherif
    Targacept Inc, 200 East First Street, Suite 300, Winston Salem, NC 27101 4165, USA
    Curr Drug Targets CNS Neurol Disord 1:349-57. 2002
  8. doi request reprint Validation of a high-throughput, automated electrophysiology platform for the screening of nicotinic agonists and antagonists
    John D Graef
    Targacept Inc, Preclinical Department, Winston Salem, NC, USA
    J Biomol Screen 18:116-27. 2013
  9. pmc Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors
    Vladimir P Grinevich
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
    Neuropharmacology 57:183-91. 2009
  10. ncbi request reprint Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties
    Patrick Lippiello
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    J Mol Neurosci 30:19-20. 2006

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia
    Aaron J Kucinski
    Department of Pathology and Anatomical Sciences, University of Buffalo, NY, USA
    Curr Pharm Biotechnol 12:437-48. 2011
    ....
  2. doi request reprint Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia
    Merouane Bencherif
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101 4165, USA
    Med Hypotheses 78:594-600. 2012
    ..In this paper we provide a model that reconciles the dopamine, glutamate and alpha7 cholinergic etiopathogenesis and is consistent with the clinical benefit derived from therapies targeted to these individual pathways...
  3. doi request reprint Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance
    Merouane Bencherif
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    Acta Pharmacol Sin 30:702-14. 2009
    ....
  4. ncbi request reprint Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors
    Merouane Bencherif
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    J Mol Neurosci 30:17-8. 2006
    ..Our findings demonstrate that potent and highly selective nAChR ligands can be designed...
  5. doi request reprint Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology?
    Merouane Bencherif
    Preclinical Research, Targacept, Inc, Suite 300, Winston Salem, NC 27101 4165, USA
    Med Hypotheses 74:281-5. 2010
    ....
  6. pmc Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases
    Merouane Bencherif
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
    Cell Mol Life Sci 68:931-49. 2011
    ..If the preclinical findings translate into human efficacy this approach could potentially provide new therapies for treating a broad array of intractable diseases and conditions with inflammatory components...
  7. ncbi request reprint Targeting neuronal nicotinic receptors: a path to new therapies
    Merouane Bencherif
    Targacept Inc, 200 East First Street, Suite 300, Winston Salem, NC 27101 4165, USA
    Curr Drug Targets CNS Neurol Disord 1:349-57. 2002
    ..Recent advances and issues relating to rational drug design based on the structure of acetylcholine binding protein are discussed...
  8. doi request reprint Validation of a high-throughput, automated electrophysiology platform for the screening of nicotinic agonists and antagonists
    John D Graef
    Targacept Inc, Preclinical Department, Winston Salem, NC, USA
    J Biomol Screen 18:116-27. 2013
    ..This study provides validation of the consistency of results using low-, medium-, and high-throughput electrophysiology platforms and supports their use for screening nicotinic compounds...
  9. pmc Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors
    Vladimir P Grinevich
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
    Neuropharmacology 57:183-91. 2009
    ....
  10. ncbi request reprint Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties
    Patrick Lippiello
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    J Mol Neurosci 30:19-20. 2006
    ..Thus, a challenge in nAChR drug design and development has been the reduction of undesirable effects that result from activity at specific nAChRs in the CNS and PNS, including cardiovascular toxicity, emesis, seizures, and hypothermia...
  11. doi request reprint TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity
    Patrick M Lippiello
    Targacept, Inc, Winston Salem, North Carolina 27101, USA
    CNS Neurosci Ther 14:266-77. 2008
    ....
  12. ncbi request reprint Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the alpha6( *) subtype
    Scott R Breining
    Department of Medicinal Chemistry, Targacept, Inc, 200 East First St, Suite 300, Winston Salem, NC 27101, USA
    Bioorg Med Chem Lett 19:4359-63. 2009
    ..The ramifications of this structure-activity relationship are discussed in the context of the design of small molecules targeting smoking cessation...
  13. doi request reprint Analgesic effects mediated by neuronal nicotinic acetylcholine receptor agonists: correlation with desensitization of α4β2* receptors
    Jiahui Zhang
    Targacept Inc, Winston Salem, NC 27101, USA
    Eur J Pharm Sci 47:813-23. 2012
    ..Thus, α4β2* nicotinic acetylcholine receptor desensitization may contribute to efficacy in the mediation of pain, and represent a mechanism for analgesic effects mediated by nicotinic agonists...
  14. ncbi request reprint QM-polarized ligand docking accurately predicts the trend in binding affinity of a series of arylmethylene quinuclidine-like derivatives at the α4β2 and α3β4 nicotinic acetylcholine receptors (nAChRs)
    David C Kombo
    Targacept, Inc, 100 North Main Street, Suite 1510, Winston Salem, NC 27101 4072, United States
    Bioorg Med Chem Lett 23:4842-7. 2013
    ..The reduction in binding affinity to the α3β4 subtype primarily results from a dampening of both coulombic and cation-π interactions. ..
  15. ncbi request reprint TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects
    Gregory J Gatto
    Preclinical Research, Targacept, Inc 200 East First Street, Suite 300, Winston Salem, NC 27101 4165, USA
    CNS Drug Rev 10:147-66. 2004
    ....
  16. doi request reprint Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition
    Nikolai B Fedorov
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
    J Pharmacol Exp Ther 328:525-32. 2009
    ..This feature could be relevant to therapeutic applications where such a selective mechanism of action is required...
  17. doi request reprint Computational studies of novel carbonyl-containing diazabicyclic ligands interacting with α4β2 nicotinic acetylcholine receptor (nAChR) reveal alternative binding modes
    David C Kombo
    Targacept, Inc, 100 North Main Street, Winston Salem, NC 27101, USA
    Bioorg Med Chem Lett 23:5105-13. 2013
    ....
  18. doi request reprint Slice XVIvo™: a novel electrophysiology system with the capability for 16 independent brain slice recordings
    John D Graef
    Targacept Inc, Preclinical Research Department, 200 East First Street, Suite 300, Winston Salem, NC 27101, USA
    J Neurosci Methods 212:228-33. 2013
    ..Overall, we have designed, created and validated a considerably cost- and space-efficient electrophysiology system that greatly improves throughput while minimizing the number of animals used in experiments...
  19. pmc Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease
    Danhui Zhang
    Center for Health Sciences, SRI International, Menlo Park, California D Z, A M, D S, M Q Research Triangle Institute, Research Triangle Park, North Carolina F I C and Targacept, Inc, Winston Salem, North Carolina M B, S L
    J Pharmacol Exp Ther 347:225-34. 2013
    ..NAChR drug treatment did not worsen parkinsonism or cognitive ability. These data suggest that nAChR agonists may be useful for the management of dyskinesias in l-DOPA-treated Parkinson's disease patients. ..
  20. doi request reprint A method for bidirectional solution exchange--"liquid bullet" applications of acetylcholine to α7 nicotinic receptors
    Nikolai Fedorov
    Targacept, Inc, Preclinical Research Department, Winston Salem, NC 27101, USA
    J Neurosci Methods 206:23-33. 2012
    ..This approach could therefore be useful for the study of rapid agonist-receptor interactions that closely mimic the physiological conditions in the synaptic cleft during bursts of neuronal activity...
  21. doi request reprint Development and optimization of a high-throughput electrophysiology assay for neuronal alpha4beta2 nicotinic receptors
    Serguei S Sidach
    Targacept, Inc, 200 East First Street, Suite 300 Winston Salem, NC 27101, USA
    J Neurosci Methods 182:17-24. 2009
    ..Our results demonstrate the utility of this electrophysiological tool for the discovery of alpha4beta2 nicotinic acetylcholine receptor ligands with potential applications in numerous clinical indications...
  22. ncbi request reprint Heterologous expression of human {alpha}6{beta}4{beta}3{alpha}5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the {alpha}5 subunit
    Vladimir P Grinevich
    Targacept, Inc, 200 East First Street, Suite 300, Winston Salem, NC 27101, USA
    J Pharmacol Exp Ther 312:619-26. 2005
    ....
  23. ncbi request reprint The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase
    Mario B Marrero
    Targacept Inc, 200 East First Street, Suite 300, Winston Salem, NC 27101 4165, USA
    J Pharmacol Exp Ther 309:16-27. 2004
    ..This study supports central and opposite roles for JAK2 and SHP-1 in the control of apoptosis and alpha7-mediated neuroprotection in PC12 cells...
  24. doi request reprint Comparative study on the use of docking and Bayesian categorization to predict ligand binding to nicotinic acetylcholine receptors (nAChRs) subtypes
    David C Kombo
    Targacept, Inc, 100 North Main Street, Winston Salem, North Carolina 27101, United States
    J Chem Inf Model 53:3212-22. 2013
    ..This result is in agreement with the fact that hydrophobicity strongly contributes in promoting nicotinic ligands binding to their cognate nAChRs. ..
  25. ncbi request reprint Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid
    Sean Shaw
    Vascular Biology Center, Medical College of Georgia, Augusta, Georgia 30912 2500, USA
    J Biol Chem 277:44920-4. 2002
    ..These findings identify novel mechanisms of receptor interactions relevant to neuronal viability and suggest novel therapeutic strategies to optimize neuroprotection...
  26. pmc In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors
    Ryan M Drenan
    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
    Neuron 60:123-36. 2008
    ..alpha6*-specific agonists or antagonists may, by targeting endogenous cholinergic mechanisms in midbrain or striatum, provide a method for manipulating DA transmission in neural disorders...
  27. ncbi request reprint Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance
    Jerry J Buccafusco
    Department of Pharmacology and Toxicology, Alzheimer s Research Center, Medical College of Georgia, Augusta, GA 30912, USA
    Trends Pharmacol Sci 26:352-60. 2005
    ..A better understanding of this phenomenon might shed new light on the role of nAChR systems in memory formation and retrieval...
  28. ncbi request reprint Angiotensin II blocks nicotine-mediated neuroprotection against beta-amyloid (1-42) via activation of the tyrosine phosphatase SHP-1
    Sean Shaw
    Vascular Biology Center, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Neurosci 23:11224-8. 2003
    ..These results demonstrate that nicotine-induced tyrosine phosphorylation of JAK2 and neuroprotection against Abeta (1-42) in PC12 cells are blocked by Ang II via AT2 receptor-induced activation of SHP-1...